Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pirlimycin is a semi-synthetic antibiotic of the lincosamide class, structurally related to clindamycin but with a six-membered ring replacing clindamycin’s five-membered ring. It is primarily used in veterinary medicine for the treatment of clinical and subclinical mastitis in lactating dairy cattle, especially those infections caused by Gram-positive bacteria such as *Staphylococcus aureus* and various *Streptococcus* species. Pirlimycin acts as a bacteriostatic agent by binding to the 50S ribosomal subunit (specifically interacting with 23S rRNA), thereby inhibiting bacterial protein synthesis through interference with peptidyl transferase activity and aminoacyl-tRNA binding. The drug is administered intramammarily, typically as its hydrochloride salt under the brand name Pirsue[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pirlimycin.